Urotensin II in Chronic Kidney Diseases and Kidney Transplants
Launched by VAKIF GUREBA TRAINING AND RESEARCH HOSPITAL · Apr 2, 2010
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
The investigators will determine the urotensin II levels in Chronic kidney disease patients, kidney transplants, and healthy controls.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age more than 18
- Exclusion Criteria:
- • Inability to give a written consent
About Vakif Gureba Training And Research Hospital
Vakıf Gureba Training and Research Hospital is a prominent healthcare institution dedicated to advancing medical knowledge and patient care through rigorous clinical research. As a sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and a multidisciplinary team of healthcare professionals to conduct innovative studies that address critical health challenges. With a commitment to ethical standards and patient safety, Vakıf Gureba fosters collaboration between researchers, clinicians, and patients to enhance the effectiveness of medical treatments and improve health outcomes within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Tufan Tukek, MD
Study Director
Vakif Gureba Training & Research Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials